美国纪念斯隆-凯特琳癌症中心Prasad S. Adusumilli等研究人员，对CAR T和检查点抑制的联用在实体瘤免疫疗法中的作用进行了回顾性总结。2019年11月11日出版的《癌细胞》杂志发表了这项成果。

研究人员表示，检查点抑制（CPB）治疗可以通过重新激活耗竭的免疫应答来引起持久的临床应答。但是，应答率仍然有限，可能是由于缺乏肿瘤反应性免疫浸润引起的。嵌合抗原受体（CAR）T细胞可提供必要的靶向肿瘤的免疫浸润液和高度特异性的抗肿瘤免疫应答。这可以通过添加CPB分子进一步放大，这些分子可用来抵消破坏最佳CAR T细胞功效的免疫抑制环境。

研究人员回顾了使用CAR T细胞和CPB药物的临床前和临床联合治疗，重点讨论了在实体瘤恶性肿瘤中的作用。

附：英文原文

Title: Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Author: Rachel Grosser, Leonid Cherkassky, Navin Chintala, Prasad S. Adusumilli

Issue&Volume: 2019/11/11

Abstract: Checkpoint blockade (CPB) therapy can elicit durable clinical responses by reactivating an exhausted immune response. However, response rates remain limited, likely secondary to a lack of a tumor-reactive immune infiltrate. Chimeric antigen receptor (CAR) T cells may provide the necessary tumor-targeting immune infiltrate and a highly specific antitumor immune response. This can be further amplified by the addition of CPB agents, which serve to counteract the immune inhibitory environment undermining optimal CAR T cell efficacy. Herein, we review preclinical and clinical combination therapy with CAR T cells and CPB agents, with a focus on solid tumor malignancies.

DOI: 10.1016/j.ccell.2019.09.006

Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30426-X